(3-iodophenyl)isopropylamine | 1152562-39-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (3-iodophenyl)isopropylamine
• 英文别名: 3-iodo-N-(propan-2-yl)aniline；3-iodo-N-propan-2-ylaniline
• CAS: 1152562-39-4
• 化学式: C₉H₁₂IN
• mdl: MFCD10688924
• 分子量: 261.105
• InChiKey: JCUCSTBSQHWRNP-UHFFFAOYSA-N

物化性质

• 沸点：
  298.6±23.0 °C(Predicted)
• 密度：
  1.588±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (3-iodophenyl)isopropylamine 在 4-乙酰氨基苯磺酰叠氮 、 四氯化钛 、 sodium carbonate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 sodium iodide 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 24.5h， 生成 methyl 2-diazo-4-[N-(3-iodophenyl)-N-isopropylamino]butanoate
  参考文献：
  名称：

  钯和钌催化的γ-氨基-α-重氮酸酯的分子内碳烯CAr-H官能团合成四氢喹啉

  摘要：

  通过过渡金属催化的α-重氮酸酯的分子内芳族CH-H官能化，已开发出一种制备四氢喹啉-4-羧酸酯的合成方法。[{Pd（IMes）（NQ）} 2 ]（IMes = 1,3-dimesitylimidazol-2-ylidene，NQ = 1,4-萘醌）和第一代Grubbs催化剂均证明是有效的。发现钌催化剂是最通用的，尽管在少数情况下钯络合物提供了更好的产率或选择性。根据DFT计算，Pd 0和Ru II催化的sp 2 -C Ar -H官能化通过不同的反应机理进行。因此，Pd 0催化反应涉及Pd从sp 2 -C Ar -H键迁移至卡宾碳原子的1,6-H迁移，然后进行还原消除过程。相比之下，在Grubbs催化剂促进的反应中，可将钌碳卡宾中间体亲电加成到芳香环上，然后进行1,2-质子迁移。

  DOI：

  10.1002/chem.201902104
• 作为产物：
  描述：

  丙酮 、 3-碘苯胺 在 三乙酰氧基硼氢化钠 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 24.0h， 以37%的产率得到(3-iodophenyl)isopropylamine
  参考文献：
  名称：

  Synthesis and SAR of (piperazin-1-yl-phenyl)-arylsulfonamides: A novel series of atypical antipsychotic agents

  摘要：

  (Piperazin-1-yl-phenyl)-arylsulfonamides were synthesized and identified to show high affinities for both 5-HT(2C) and 5-HT(6) receptors. Among them, naphthalene-2-sulfonic acid isopropyl-[3-(4-methyl-piperazin- 1-yl)-phenyl]-amide (6b) exhibits the highest affinity towards both 5-HT(2C) (IC(50) = 4 nM) and 5-HT(6) receptors (IC(50) = 3 nM) with good selectivity over other serotonin (5-HT(1A), 5-HT(2A), and 5-HT(7)) and dopamine (D(2)-D(4)) receptor subtypes. In 5-HT(2C) and 5-HT(6) receptor functional assays, this compound showed considerable antagonistic activity for both receptors. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.06.150

文献信息

• SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF
  申请人：Xiamen University

  公开号：US20200165246A1

  公开（公告）日：2020-05-28

  A type of substituted penta-fused hexa-heterocyclic compounds having selective inhibition for PIKfyve kinase, a pharmaceutically acceptable salt and pharmaceutically acceptable solvate thereof, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for preventing or treating a disease associated with PIKfyve in vivo, in particular in the manufacture of a medicament for preventing or treating tumor growth and metastasis.

  一种替代的五重融合六元杂环化合物，具有对PIKfyve激酶的选择性抑制作用，其药学上可接受的盐及其药学上可接受的溶剂，其制备方法，包括这些化合物的药物组合物，以及在制备用于预防或治疗与PIKfyve相关疾病的药物中使用这些化合物，特别是在制备用于预防或治疗肿瘤生长和转移的药物中。
• Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof
  申请人：Xiamen University

  公开号：US11352354B2

  公开（公告）日：2022-06-07

  A type of substituted penta-fused hexa-heterocyclic compounds having selective inhibition for PIKfyve kinase, a pharmaceutically acceptable salt and pharmaceutically acceptable solvate thereof, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for preventing or treating a disease associated with PIKfyve in vivo, in particular in the manufacture of a medicament for preventing or treating tumor growth and metastasis.

  一种对PIKfyve激酶具有选择性抑制作用的取代五融合六六环化合物、其药学上可接受的盐和药学上可接受的溶液、其制备方法、包含这些化合物的药物组合物，以及这些化合物在制造预防或治疗体内PIKfyve相关疾病的药物中的用途，特别是在制造预防或治疗肿瘤生长和转移的药物中的用途。
• MODULATORS OF THE RELAXIN RECEPTOR 1
  申请人：The United States of America, as Represented by Secretary, Department of Health and Human Service

  公开号：US20170144984A1

  公开（公告）日：2017-05-25

  Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R 1 , and R 2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for therapeutic intervention in a facet of mammalian health that is mediated by a human relaxin receptor 1.